Шкала ризику смертності, пов'язаної з трансплантацією — an HCT-CI-style comorbidity index walkthrough, from organ-system assessment to conditioning-intensity decisions
Long before a conditioning regimen is chosen, transplant teams systematically evaluate the patient's baseline organ function and pre-existing conditions. A structured comorbidity index — conceptually modeled on tools like the Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) — captures cardiac, pulmonary, hepatic, renal, and other organ-specific conditions that add risk independent of the underlying malignancy.
Allogeneic and autologous hematopoietic cell transplant impose enormous physiologic stress: high-dose or reduced-intensity conditioning, prolonged cytopenia, infection risk, and — for allogeneic transplant — graft-versus-host disease. Patients enter this process with widely varying baseline organ reserve.
A structured comorbidity assessment captures conditions such as: • Cardiac: prior arrhythmia, valvular disease, reduced ejection fraction, coronary disease • Pulmonary: reduced DLCO or FEV1, prior pulmonary infections, restrictive or obstructive disease • Hepatic: elevated transaminases, prior hepatitis, cirrhosis, portal hypertension • Renal: elevated creatinine, reduced glomerular filtration rate, prior dialysis • Other: prior solid malignancy, psychiatric disease, diabetes, obesity, infection history
Each domain is assessed through history, physical examination, and objective testing (echocardiogram, pulmonary function tests, liver panel, creatinine clearance) — producing a structured, reproducible pre-transplant risk profile rather than a purely subjective impression.
The conceptual value of a structured index over informal clinical judgment is reproducibility: two different clinicians assessing the same patient should reach a similar composite picture, enabling risk communication and comparison across transplant centers.
Once comorbidities are identified, each is assigned a weighted point value reflecting its established association with non-relapse mortality. Points are summed across all organ systems into a single composite comorbidity index score — the foundation for downstream risk stratification.
Not all comorbidities carry equal risk. Weighted scoring systems assign point values calibrated against observed non-relapse mortality (NRM) in large transplant cohorts — a comorbidity strongly associated with post-transplant death (e.g., moderate-to-severe pulmonary impairment) receives more points than one with a weaker association (e.g., well-controlled prior infection).
Conceptually: • Mild, well-controlled conditions: 1 point • Moderate organ impairment: 2 points • Severe organ impairment or multiple affected domains: 3 points
The composite score is simply the sum of points across all identified comorbidities. A patient with well-controlled hepatic disease (1 point) and moderate pulmonary impairment (3 points) would have a composite score of 4 — quite different in projected risk from a patient with the same two domains affected but each only mildly (2 points total).
This simulator's slider represents that composite, illustrative 0–10 score directly, letting you explore how the downstream risk category and estimated mortality risk shift as the total burden of comorbidity rises.
A composite comorbidity score is only useful clinically once it is mapped onto risk categories with distinct expected outcomes. Patients are typically stratified into low, intermediate, and high comorbidity risk groups, each associated with a different range of expected non-relapse mortality after transplant.
Turning a continuous composite score into discrete risk categories serves two purposes: it simplifies communication with patients and families, and it creates actionable thresholds that can inform treatment planning discussions.
In this simulator's illustrative mapping: • Low risk: composite score 0–2 — lowest expected non-relapse mortality band • Intermediate risk: composite score 3–4 — moderate expected non-relapse mortality • High risk: composite score ≥5 — highest expected non-relapse mortality band
These category boundaries are illustrative simplifications of the general HCT-CI concept and are not a substitute for a validated clinical scoring tool. Real comorbidity indices are calibrated against large, prospectively studied transplant cohorts, and cutoffs may differ across published versions of the index and across transplant centers.
Importantly, risk category is one input among several — it informs, but does not by itself dictate, whether a patient proceeds to transplant, and with which conditioning approach.
A key principle: risk category reflects statistical association observed across populations of patients, not a deterministic prediction for any single individual. Two patients with the same composite score can have meaningfully different actual outcomes.
Comorbidity risk is only one axis of pre-transplant risk assessment. The full picture integrates the comorbidity-based score alongside disease risk index (how aggressive or advanced the underlying malignancy is) and the planned conditioning intensity or transplant type — combining into a comprehensive assessment used for treatment planning.
A patient's overall transplant risk is multidimensional. Comorbidity burden captures baseline organ reserve and general physiologic fitness, but it says nothing about how aggressive the underlying disease is, nor about how intensively the conditioning regimen will stress the body.
Three axes are typically integrated:
1. Comorbidity-based risk score — organ-system burden, as established in Stages 1–3 2. Disease risk index — cytogenetics, molecular markers, remission status, and disease subtype, reflecting the aggressiveness and relapse risk of the underlying malignancy 3. Planned conditioning intensity / transplant type — reduced-intensity conditioning (RIC), myeloablative conditioning (MAC), or non-myeloablative approaches, each imposing different degrees of physiologic stress and different balances of relapse risk versus toxicity risk
A patient with low comorbidity burden but high-risk, aggressive disease might still be steered toward more intensive conditioning despite the trade-off in toxicity risk, because under-treating the malignancy carries its own mortality risk. Conversely, a patient with high comorbidity burden and lower-risk disease may be better served by a gentler approach. The integrated assessment is what allows this kind of nuanced, individualized reasoning rather than a single-axis decision.
The transplant-related mortality risk score does not exist in a vacuum — its primary clinical purpose is to inform the choice between conditioning approaches. A higher risk score may favor reduced-intensity conditioning (RIC) over myeloablative conditioning (MAC), directly linking risk assessment to a concrete treatment decision.
Myeloablative conditioning (MAC) delivers higher-dose chemotherapy and/or radiation, more completely ablating host marrow and often providing stronger disease control — but at the cost of greater regimen-related toxicity, which is harder to tolerate for patients with reduced organ reserve.
Reduced-intensity conditioning (RIC) delivers lower-dose, less physiologically stressful conditioning, relying more heavily on the graft-versus-tumor effect for disease control — generally better tolerated by patients with higher comorbidity burden, though historically associated with somewhat higher relapse risk in some disease settings.
A higher transplant-related mortality risk score — reflecting greater baseline organ-system burden — shifts this trade-off calculation toward favoring reduced-intensity approaches, because the marginal toxicity risk from myeloablative conditioning becomes proportionally larger relative to the potential disease-control benefit. This is precisely the "conditioning fit" logic this simulator's metrics panel illustrates: as the comorbidity score rises alongside a myeloablative conditioning plan, the appropriateness signal flags the elevated risk and points toward reconsidering intensity.
This decision is never made on comorbidity score alone — disease risk, donor availability, patient preference, and center experience all factor in — but the comorbidity-based mortality risk score is one of the most influential and reproducible single inputs into that conversation.
A recurring theme across pre-transplant risk assessment: addressing modifiable comorbidities before transplant — optimizing cardiac function, treating reversible pulmonary or hepatic issues — can sometimes lower the effective risk score itself, potentially widening the set of conditioning options available to a patient.